Akari Therapeutics (AKTX) Competitors $1.30 -0.01 (-0.41%) Closing price 03/27/2025 03:58 PM EasternExtended Trading$1.30 +0.00 (+0.38%) As of 03/27/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AKTX vs. EDIT, ADAP, SLN, SGMT, COYA, NKTX, DERM, FATE, ELUT, and KYTXShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Editas Medicine (EDIT), Adaptimmune Therapeutics (ADAP), Silence Therapeutics (SLN), Sagimet Biosciences (SGMT), Coya Therapeutics (COYA), Nkarta (NKTX), Journey Medical (DERM), Fate Therapeutics (FATE), Elutia (ELUT), and Kyverna Therapeutics (KYTX). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Editas Medicine Adaptimmune Therapeutics Silence Therapeutics Sagimet Biosciences Coya Therapeutics Nkarta Journey Medical Fate Therapeutics Elutia Kyverna Therapeutics Akari Therapeutics (NASDAQ:AKTX) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk. Does the media favor AKTX or EDIT? In the previous week, Editas Medicine had 3 more articles in the media than Akari Therapeutics. MarketBeat recorded 6 mentions for Editas Medicine and 3 mentions for Akari Therapeutics. Editas Medicine's average media sentiment score of 0.32 beat Akari Therapeutics' score of 0.15 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Editas Medicine 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend AKTX or EDIT? Editas Medicine has a consensus target price of $6.83, suggesting a potential upside of 425.64%. Given Editas Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Editas Medicine is more favorable than Akari Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Editas Medicine 2 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.07 Is AKTX or EDIT more profitable? Akari Therapeutics has a net margin of 0.00% compared to Editas Medicine's net margin of -340.96%. Akari Therapeutics' return on equity of 0.00% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A N/A N/A Editas Medicine -340.96%-80.13%-50.99% Which has more risk and volatility, AKTX or EDIT? Akari Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Which has preferable earnings & valuation, AKTX or EDIT? Akari Therapeutics has higher earnings, but lower revenue than Editas Medicine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$10.01MN/AN/AEditas Medicine$32.31M3.34-$153.22M-$2.88-0.45 Does the MarketBeat Community prefer AKTX or EDIT? Editas Medicine received 51 more outperform votes than Akari Therapeutics when rated by MarketBeat users. Likewise, 53.23% of users gave Editas Medicine an outperform vote while only 50.19% of users gave Akari Therapeutics an outperform vote. CompanyUnderperformOutperformAkari TherapeuticsOutperform Votes26250.19% Underperform Votes26049.81% Editas MedicineOutperform Votes31353.23% Underperform Votes27546.77% Do institutionals & insiders hold more shares of AKTX or EDIT? 5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 38.9% of Akari Therapeutics shares are owned by insiders. Comparatively, 1.9% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryEditas Medicine beats Akari Therapeutics on 10 of the 15 factors compared between the two stocks. Remove Ads Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.57M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.57%4.01%P/E RatioN/A7.2023.1319.03Price / SalesN/A226.01383.8993.17Price / CashN/A65.6738.1634.64Price / Book-43.336.476.944.33Net Income-$10.01M$141.90M$3.20B$247.06M7 Day Performance-15.03%-3.20%-2.32%-0.37%1 Month Performance49.43%-5.64%2.84%-3.85%1 Year Performance-29.73%-7.47%10.75%1.27% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari TherapeuticsN/A$1.30-0.4%N/A-27.8%$34.57MN/A0.009Analyst ForecastGap DownEDITEditas Medicine4.0563 of 5 stars$1.41-3.4%$6.83+384.6%-82.5%$117.00M$32.31M-0.55230ADAPAdaptimmune Therapeutics2.6562 of 5 stars$0.46+1.4%$2.79+510.4%-86.1%$116.86M$175.04M-2.08490Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpSLNSilence Therapeutics2.2141 of 5 stars$3.90-0.3%$40.67+942.7%-83.1%$116.73M$43.26M-2.48100Positive NewsSGMTSagimet Biosciences2.7919 of 5 stars$3.78+1.1%$23.00+508.5%-34.4%$115.95M$2M-2.648Short Interest ↓COYACoya Therapeutics2.1954 of 5 stars$6.85+5.5%$16.25+137.2%-28.6%$114.44M$9.55M-10.546Analyst ForecastAnalyst RevisionNews CoverageNKTXNkarta2.9035 of 5 stars$1.62-2.4%$15.00+825.9%-82.2%$114.32MN/A-0.86140Earnings ReportAnalyst ForecastNews CoverageGap UpDERMJourney Medical2.5762 of 5 stars$5.31+1.1%$9.67+82.0%+52.2%$110.93M$57.77M-5.6590Earnings ReportFATEFate Therapeutics3.9505 of 5 stars$0.97+2.6%$5.50+469.2%-88.0%$110.74M$13.63M-0.59550Positive NewsELUTElutia3.9503 of 5 stars$3.20+0.6%$9.00+181.3%-16.4%$110.60M$24.38M-1.23180Short Interest ↓News CoverageGap UpKYTXKyverna Therapeutics1.4584 of 5 stars$2.54+1.6%$18.40+624.4%-90.2%$109.66M$7.03M0.0096Earnings ReportNews CoverageGap Up Remove Ads Related Companies and Tools Related Companies Editas Medicine Competitors Adaptimmune Therapeutics Competitors Silence Therapeutics Competitors Sagimet Biosciences Competitors Coya Therapeutics Competitors Nkarta Competitors Journey Medical Competitors Fate Therapeutics Competitors Elutia Competitors Kyverna Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKTX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKTX Stock Free AKTX Stock Alerts